



MARKET RELEASE

21 March 2018

Noxopharm Limited

TRADING HALT

The securities of Noxopharm Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 23 March 2018 or when the announcement is released to the market.

Security Code: NOX

Cheng Tang
SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office and

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

21 March 2018

Ms Cheng Tang
Adviser

Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au

By Email: tradinghaltsmelbourne@asx.com.au

Dear Cheng,

NOXOPHARM LIMITED – TRADING HALT

The Company requests an immediate trading halt in the securities of Noxopharm Limited (ASX:NOX) pending the release of an ASX announcement regarding a proposed capital raising. It is expected the trading halt will end on the earlier of the commencement of normal trading on Friday 23 March 2018, or when the announcement on the capital raising is released to the market

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on (02) 9299 9690.

For and on behalf of the Board,

Yours faithfully,

David Franks
Company Secretary